Power3 Medical’s Goldknopf to Give Plenary Address to the European Molecular Histopathology Symposium

StemTroniX, Inc., a Texas corporation ("StemTroniX"), and Power3 Medical Products, Inc. (OTCBB:PWRM) announced today that a plenary address entitled "The Genesis of Prototype Biomarkers for Identification and Use of Stem Cells for Therapeutics of Alzheimer’s Disease” will be delivered by Ira L. Goldknopf, PhD, Power3’s President and Chief Scientific Officer, to the European Molecular Histopathology Symposium on The Impact of Personalized Medicine, April 29, 2010, in Chantilly, France, organized by Ventana Medical Systems, a member of the Roche Group.

The focus of the presentation is on the progress Power3 and StemTroniX have made towards enhanced effectiveness of Alzheimer’s disease therapy by combining StemTroniX’s patented and patent pending adult stem cell regenerative medicine technologies with Power3’s patent pending blood serum adult stem cell protein biomarkers and diagnostic technologies. StemTroniX’s technologies include a licensed patent and several patent disclosures for monitoring of stem cell therapy, technology to aid in the viability of adult stem cells, injection technology, and non-invasive imaging technology. These technologies complement Power3’s technologies for Alzheimer’s specific diagnosis, multiple forms of Alzheimer’s disease, response to Alzheimer’s drug therapy, predictive drug response, and discovery of more clinically relevant tissue, blood and adult stem cell biomarkers.

"Biomarkers for the support of autologous (a patient’s own) stem cell therapies of Alzheimer’s disease are needed to light the way to true recovery, i.e. to the restoration of the patient through repair and regeneration of the brain tissue ravaged by the disease. Nothing less is acceptable for true regenerative medicine,” said Goldknopf. "To achieve these ends, we believe it is necessary to set the bar high, so that we can find biomarkers related to the restoration of normality, not only with respect to symptoms, but also with respect to correcting the underlying and devastating pathophysiology of Alzheimer’s disease. We will demonstrate steps already taken towards this goal as well as illustrate essential requirements for the way forward.”

"In conjunction with the upcoming acquisition of StemTroniX by Power3, and recent patent filings, this presentation marks a significant step towards the joint goal of StemTroniX and Power3, to fulfill the promise of personalized medicine by providing desperately needed diagnosis and targeted therapy for Alzheimer’s disease,” said Helen R. Park, StemTroniX’s CEO.

Power3 Medical Products

Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance.

For more information, please visit http://www.power3medical.com

StemTroniX

StemTroniX, Inc. is a medical biotechnology company that is committed to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients. Autologous adult stem cell therapy is the process of using an individual's own stem cells for the purpose of repairing and regenerating damaged tissue. StemTroniX also provides a patented system to augment this process in a non-invasive method for in-body monitoring of the stem cells at the site of injury as they are being introduced into the patients.

For more information, please visit http://www.stemtronix.com

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.